Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2006-04-27
2010-11-02
Aeder, Sean E (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Reexamination Certificate
active
07824849
ABSTRACT:
The invention provides dendritic cell (DC) preparations that present a telomerase reverse transcriptase (TRT) peptide in the context of an MHC class I or MHC class II molecule. The DCs may be pulsed with a TRT polypeptide, or may comprise a recombinant polynucleotide encoding TRT. The invention also describes the use of such compositions for the prevention and treatment of cancers and other diseases.
REFERENCES:
patent: 4839290 (1989-06-01), Kaieda et al.
patent: 5583016 (1996-12-01), Villeponteau et al.
patent: 5645986 (1997-07-01), West et al.
patent: 5648219 (1997-07-01), MacKay et al.
patent: 5656638 (1997-08-01), Gaeta et al.
patent: 5747317 (1998-05-01), Cao
patent: 5770422 (1998-06-01), Collins
patent: 5853719 (1998-12-01), Nair et al.
patent: 5858777 (1999-01-01), Villeponteau et al.
patent: 5866115 (1999-02-01), Kanz et al.
patent: 5871728 (1999-02-01), Thomson et al.
patent: 5874307 (1999-02-01), Ohno et al.
patent: 5917025 (1999-06-01), Collins
patent: 5962318 (1999-10-01), Rooney et al.
patent: 5962320 (1999-10-01), Robinson
patent: 5968506 (1999-10-01), Weinrich et al.
patent: 5972627 (1999-10-01), Galy
patent: 5981707 (1999-11-01), Harrington et al.
patent: 5994126 (1999-11-01), Steinman et al.
patent: 6004807 (1999-12-01), Banchereau et al.
patent: 6008004 (1999-12-01), Olweus et al.
patent: 6010905 (2000-01-01), Cohen et al.
patent: 6015554 (2000-01-01), Galy
patent: 6017527 (2000-01-01), Maraskovsky et al.
patent: 6033669 (2000-03-01), Jondal
patent: 6077519 (2000-06-01), Storkus et al.
patent: 6080409 (2000-06-01), Laus et al.
patent: 6093809 (2000-07-01), Cech et al.
patent: 6166178 (2000-12-01), Cech et al.
patent: 6224870 (2001-05-01), Segal
patent: 6261836 (2001-07-01), Cech et al.
patent: 6277613 (2001-08-01), De Lange et al.
patent: 6306388 (2001-10-01), Nair et al.
patent: 6387701 (2002-05-01), Nair et al.
patent: 6440735 (2002-08-01), Gaeta
patent: 6670186 (2003-12-01), Nair et al.
patent: 7101705 (2006-09-01), Nair et al.
patent: 7105157 (2006-09-01), Nair et al.
patent: 2003/0104432 (2003-06-01), Xu et al.
patent: 2006/0057130 (2006-03-01), Nair et al.
patent: 689672 (1999-08-01), None
patent: 1 093 381 (2003-08-01), None
patent: WO 93/20185 (1993-10-01), None
patent: WO 94/02156 (1994-02-01), None
patent: WO 94/21287 (1994-09-01), None
patent: WO 94/28113 (1994-12-01), None
patent: WO 95/34638 (1995-12-01), None
patent: WO 96/01835 (1996-01-01), None
patent: WO 96/23060 (1996-08-01), None
patent: WO 97/04802 (1997-02-01), None
patent: WO 97/07200 (1997-02-01), None
patent: WO 97/22349 (1997-06-01), None
patent: WO 97/24447 (1997-07-01), None
patent: WO 97/29182 (1997-08-01), None
patent: WO 97/29183 (1997-08-01), None
patent: WO 97/34472 (1997-09-01), None
patent: WO 97/40182 (1997-10-01), None
patent: WO 97/41210 (1997-11-01), None
patent: WO 98/01538 (1998-01-01), None
patent: WO 98/07838 (1998-02-01), None
patent: WO 98/14592 (1998-04-01), None
patent: WO 98/14593 (1998-04-01), None
patent: WO 98/15615 (1998-04-01), None
patent: WO 98/21343 (1998-05-01), None
patent: WO 98/23759 (1998-06-01), None
patent: WO 98/37181 (1998-08-01), None
patent: WO 98/46083 (1998-10-01), None
patent: WO 98/55597 (1998-12-01), None
patent: WO 98/59040 (1998-12-01), None
patent: WO 98/59046 (1998-12-01), None
patent: WO 99/01560 (1999-01-01), None
patent: WO 99/25812 (1999-05-01), None
patent: WO 99/50392 (1999-10-01), None
patent: WO 99/51255 (1999-10-01), None
patent: WO 99/63050 (1999-12-01), None
patent: WO 99/63945 (1999-12-01), None
patent: WO 00/02581 (2000-01-01), None
patent: WO 00/08191 (2000-02-01), None
patent: WO 00/15264 (2000-03-01), None
patent: WO 00/25813 (2000-05-01), None
patent: WO 00/28000 (2000-05-01), None
patent: WO 00/61766 (2000-10-01), None
patent: WO 00/73420 (2000-12-01), None
patent: WO 01/60391 (2001-08-01), None
patent: WO 02/094213 (2002-11-01), None
patent: WO 03/038047 (2003-05-01), None
Kyo et al (Biochemical and Biophysical Research Communications, 1997, 241:498-503).
Alexandre-Gross, D. et al., “High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy,”J. Clin. Invest. 113(3):425-33 (2004).
Altuvia, Y. et al., “A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets,”Human Immunol. 58:1-11 (1997).
Altuvia, Y. et al., “Ranking potential binding peptides to MHC molecules by a computational threading appraoch,”J. Mol. Biol. 249:244-50 (1995).
Arai, J. et al., “Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes,”Blood 97:2903-7 (2001).
Ayyoub, M. et al., “Lack of tumor recognition by hTERT peptide 540-548-specific CD8+T cells from melanoma patients reveals inefficient antigen processing,”Eur. J. Immunol. 31:2642-51 (2001).
Baar, J., “Clinical applications of dendritic cell cancer vaccines,”The Oncologist 4:140-4 (1999).
Banchereau, J. et al., “Dendritic cells and the control of immunity,”Nature 392:245-52 (1998).
Banchereau, J. et al., “Immunobiology of dendritic cells,”Annu. Rev. Immunol. 18:767-811 (2000).
Bellone, M. et al., “In Vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells,”Eur. Immunol. 24:2691-8 (1994).
Bellone, M. et al., “Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells,”J. Immunol. 158:783-9 (1997).
Boczkowski, D. et al., “Dendritic cells pulsed with RNA are potent antigen-presenting cells in Vitro and in Vivo,”J. Exp. Med. 184:465-72 (1996).
Broccoli, D. et al., “Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2,”Nature Genet. 17:231-5 (1997).
Broccoli, D. et al., “Telomerase activity in normal and malignant hematopoietic cells,”Proc. Natl. Acad. Sci. USA 92:9082-6 (1995).
Brun, C. et al., “Proteins that bind to double-stranded regions of telomeric DNA,”Trends in Cell Biol. 7:317-24 (1997).
Brusic, V. et al., “Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network,”Bioinformatics 14(2):121-30 (1998).
Butterfield, L. et al., “DNA and dendritic cell-based genetic immunization against cancer,”Gene Therapy of Cancer, Chapter 18, pp. 285-298, Lattime & Gerson, Eds., Academic Press, San Diego, California (1999).
Carter, J., “Epitope prediction methods,”Meth. Mol. Biol. 36:193-206 (1994) 1 page.
Chong, L. et al., “A human telomeric protein,”Science270:1663-7 (1995).
Cong, Y. et al., “The human telomerase catalytic subunit HTERT: organization of the gene and characterization of the promoter,”Human Mol. Genet. 8(1):137-42 (1999).
Deavin, A. et al., “Statistical comparison of established T-cell epitope predictors against a large database of human and murine antigens,”Mol. Immunol. 33(2):145-55 (1996), Abstract only.
Domchek, S. et al., “Immunological and clinical outcomes following telomerase peptide vaccination in patients with metastatic breast cancer,” 97thAACR Annual Meeting, Washington, DC, Abstract No. 4003 (Apr. 1-5, 2006).
Frolkis, M. et al., “Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors,”Cancer Gene Therapy 10:239-49 (2003).
Geron Corporation, Menlo Park, CA—Press Release, “Geron Announces Initiation of Duke Prostate Cancer Clinical Trial Using Telomerase Immunotherapy,” (Oct. 30, 2001).
Gershoni, J. et al., “Combinatorial libraries, epitope structure and the prediction of protein conformations,”Immunol. Today 18(3)108-10 (1997), 1 page.
Gilboa, E. et al., “Immunotherapy of cancer with dendritic-cell-based vaccines,”Cancer Immunol. Immunother. 46:82-7 (1998).
Greaves, M., “Is telomerase act
Aeder Sean E
Earp David J.
Geron Corporation
Mool Leslie A.
LandOfFree
Cellular telomerase vaccine and its use for treating cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cellular telomerase vaccine and its use for treating cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cellular telomerase vaccine and its use for treating cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4247273